JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M107454200 on August 6, 2001

J. Biol. Chem., Vol. 276, Issue 42, 38929-38933, October 19, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/42/38929    most recent
M107454200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Della-Bianca, V.
Right arrow Articles by Della Valle, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Della-Bianca, V.
Right arrow Articles by Della Valle, G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Neurotrophin p75 Receptor Is Involved in Neuronal Damage by Prion Peptide-(106-126)*

Vittorina Della-BiancaDagger , Filippo RossiDagger §, Ubaldo Armato, Ilaria Dal-Pra, Claudio CostantiniDagger , Giovanni Perini||, Valeria Politi||, and Giuliano Della Valle||

From the Dagger  Department of Pathology, Section of General Pathology, University of Verona, Strada Le Grazie 8, Verona 37134, Italy, the  Department of Biomedical and Surgical Sciences, Section of Histology and Embryology, University of Verona, Strada Le Grazie 8, Verona 37134, Italy, and the || Department of Biology, University of Bologna, Via Selmi 3, Bologna 40126, Italy

Received for publication, August 3, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

In this work we have investigated the molecular basis of the neuronal damage induced by the prion peptide by searching for a surface receptor whose activation could be the first step of a cascade of events responsible for cell death. By using a human neuroblastoma cell line lacking all the neurotrophin receptors and derived clones expressing the full-length or truncated forms of the low affinity neurotrophin receptor (p75NTR), we have been able to demonstrate that the neuronal death induced by the prion protein fragment PrP-(106-126) is an active process mediated by a) the binding of the peptide to the extracellular region of p75NTR, b) the signaling function of the intracytoplasmic region of the receptor, and c) the activation of caspase-8 and the production of oxidant species.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The aetiological agent of the prion diseases, a set of sporadic, genetic, and infectious neurodegenerative disorders affecting humans and animals, has been proposed to be an aberrant isoform of the cell surface glycoprotein (PrPC)1 named Scrapie prion protein (PrPSc), which arises posttranslationally via conformational changes converting PrPC into PrPSc (1, 2). So far, the mechanisms by which the extracellular deposition of PrPSc, a protein characterized by its high content of beta -pleated sheet and ability to form amyloid fibrils, elicits the neuropathological changes of the prion diseases, i.e. spongiform degeneration, neuronal loss, and appearance of reactive astrocytes and microglial cells (1), had remained unknown.

In recent years, it has been demonstrated that a prion protein fragment, PrP-(106-126), could induce neuronal death by apoptosis in rat hippocampal cultures (3). This peptide mimics the physico-chemical properties of PrPSc by exhibiting a prevalent beta -pleated structure and forming amyloid fibrillar aggregates that are partially resistant to proteolysis (4). The ability of PrP-(106-126) to elicit a neurotoxic effect has been widely confirmed (5-8) and, hence, it is considered a valid model for studies into the mechanisms of neuronal damage by prions. So far, the knowledge of such mechanisms had remained rather limited despite a series of recent findings, the most significant of which are: a) the binding of the prion peptide to cellular prion protein PrPC and the consequent inhibition of PrPC function (9); b) the perturbation of ion (especially calcium) homeostasis (6, 10, 11); c) the induction of oxidative stress (12); and d) the cooperative pathogenetic role of the activation of microglia with production of oxidant species (5).

In the search for a prion receptor we focused our attention on the p75 low affinity NGF receptor, which belongs to the family of death receptors (13) and can trigger apoptosis (14-16). The rationale of this investigation was 2-fold. First, it has been observed that PrP-(106-126) exhibits a prevalent beta -sheet structure and forms fibrillar aggregates similarly to beta -amyloid peptides (4). Second, the beta -amyloid peptides of Alzheimer's disease may exert their neurotoxic action via an interaction with p75NTR (17-19). The data herein presented support the view that the prion peptide-mediated cell damage occurs through its interaction with the p75 neurotrophin receptor.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Materials-- The peptide PrP-(106-126), synthesized as previously described (3), was a generous gift of Prof. S. Salvadori (Department of Pharmaceutical Sciences, University of Ferrara, Italy) or was purchased from Bachem (Budendorf). 125I-PrP-(106-126) was prepared by Amersham Pharmacia Biotech. Scrambled PrP-(106-126) was a kind gift of Dr. M. Salmona (Istituto Mario Negri, Milano). Peptides were dissolved in 200 mM phosphate buffer, pH 5.0, and aged for 2-3 days at 37 °C to increase fibrillogenesis, which was measured with the Thioflavin test. Goat polyclonal antibody sc-6189 against a peptide mapping at the amino terminus of human p75NTR was purchased from Santa Cruz Biotechnology. All the chemicals, when not indicated, were from Sigma.

p75NTR Constructs-- All p75NTR constructs were generated via different strategies. The wild type p75NTR construct was produced by cloning the p75NTR cDNA into the pCEP4beta vector within the PvuII site. The deletion mutants p75Delta ICD and p75Delta ECD were obtained by polymerase chain reaction utilizing specific primers that introduce either a deletion of the carboxyl-terminal domain or specific internal deletions within the extracellular cysteine-rich domains or the intracellular domains. The scheme of full-length p75NTR and of the truncated forms of the receptor is reported in Fig. 1A.

Cell Clones and Detection of p75NTR mRNA and Proteins-- The parental neuroblastoma SK-N-BE cells (20) (BENTR-free) were grown in RPMI 1640 medium containing fetal bovine serum (15% v/v) and antibiotics. The cells were transfected with the different pCEP4beta -p75NTR constructs using the polyethylene-immine method. After transfection, the cells were split and grown in RPMI medium containing hygromycin (150 µg/ml) to allow for the selection of positive clones. Surviving clones were picked, expanded, and characterized for expression of both wild type and mutated p75NTR proteins. All clones were tested for expression of mRNA by Northern blot analysis (Fig. 1C) as previously described (20). Briefly, total RNA was extracted from cell clones by Tri-Reagent (Sigma) following manufacturer protocol. 15 µg of total RNA have been loaded per lane and run on a 3% formaldeyde,1.5% agarose gel, transferred to a nylon membrane (Hybond N+, Amersham Pharmacia Biotech) and probed with the p75NTR full-length cDNA labeled with 32P using MegaPrime kit (Amersham Pharmacia Biotech) following the manufacturer protocol. For the Western blot analysis cell lysates were processed as previously described (20), and the expression of p75NTR protein was tested using 9992 rabbit polyclonal antiserum (a gift from Dr. M. V. Chao), which recognizes the intracellular region of the receptor (Fig. 1D). For each p75NTR construct, a battery of cell clones expressing comparable levels of either full-length or truncated proteins was chosen for the experimental work. The correct localization of the p75NTR proteins in the plasmamembrane was detected immunohistochemically (Fig. 1B). Cells were permeabilized with 0.1% Triton X-100 and then stained with the rabbit polyclonal antiserum (9992), or a mouse monoclonal antibody (ME 20.4) (a gift from Dr. M. V. Chao) raised against the p75NTR extracellular region (20).

Cytotoxicity of PrP-(106-126)-- Cells were plated (10,000/cm2) in RPMI medium supplemented with fetal bovine serum (15% v/v), glutamine (2.0 mM), gentamycine (50 µg/ml) and hygromycin (150 µg/ml in the case of the transfected cells) and maintained at 37 °C in humidified atmosphere of air with 5% (v/v) CO2 added. Two days later, the growth medium was replaced with fresh RPMI medium containing fetal bovine serum (1% v/v) and PrP-(106-126) or staurosporine. When required the inhibitors of caspases Z-Val-Ala-DL-Asp-fluoromethyl-ketone (Z-VAD-FMK) or Z-Ile-Glu-Thr-Asp-fluoromethyl-ketone (Z-IETD-FMK) (Calbiochem) or of NADPH oxidase diphenyleneiodonium were added 2 h before prion peptide or staurosporine. Specimens were sampled at various intervals thereafter. The cell damage was assessed by means of epifluorescence microscopy after staining the plated cells with a solution 1:1 (v/v) of acridine orange (0.1 mg/ml in phosphate-buffered saline; filter setting for fluorescein isothiocyanate) and ethidium bromide (0.1 mg/ml in phosphate-buffered saline; filter setting for rhodamine) according to Spector et al. (21).

Binding Assay-- Cells plated as for cytotoxic assays were incubated with 0.4 nM 125I-PrP-(106-126) in the presence or absence of 1000-fold excess of cold aggregated peptide for 3 h at 4 °C. The cells were next rinsed with ice-cold phosphate-buffered saline and lysed in 1.0 M NaOH, and the lysates were subjected to gamma  counting. For Scatchard analysis of the aggregated PrP-(106-126) binding to p75NTR-expressing cells 0.4 nM 125I-PrP-(106-126) was used as tracer and increasing concentrations of aggregated cold peptide were used as competitor. For competition analysis 0.4 nM 125I-PrP-(106-126) was used as tracer and increasing concentrations of NGF and antibody sc-6189 were used. For each point of the Scatchard analysis nonspecific binding, determined with a 1000-fold excess of cold competitor, was subtracted from total binding.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

We have studied the effects of PrP-(106-126) on both the human neuroblastoma SK-N-BE cells (BENTR-free), which express neither p75NTR nor any of the high affinity neurotrophin receptors (Trks) (20), and SK-N-BE cell clones expressing the full-length p75NTR (BEp75) (Fig. 1). The cell damage was analyzed by double staining of the specimens with both the cell-permeable acridine orange and the cell-impermeable ethidium bromide (21) as shown in Fig. 2. The results of these analyses, summarized in Fig. 3, A and B, demonstrate that PrP-(106-126) could induce cell death in BEp75 cell clones, while being totally harmless for BENTR-free parental cells and for SK-N-BE cells transfected with an empty pCEP4beta vector (not shown). Importantly, the neurotoxic action of PrP-(106-126) on BEp75 cell clones was detectable already at very low concentrations (Fig. 3C). Scrambled PrP-(106-126) was unable to induce cell death in either cell clones (not shown). To our knowledge, this is the first evidence that p75NTR is involved in the neurotoxic activity of prion peptide.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 1.   Expression of p75NTR in cell clones. A, schematic depiction of the full-length and truncated p75NTR proteins expressed in transfected SK-N-BE neuroblastoma cells. Specifically: p75, full-length receptor; p75Delta ECD, lacking the extracellular region from amino acids 37-229; p75Delta ICD, lacking the entire cytoplasmic region from amino acid 280. B, localization of the p75NTR protein in the plasmamembrane by immunostaining with 9992 antiserum in BENTR-free, BEp75, and BEp75Delta ECD cell clones and with monoclonal antibody ME20.4 in BEp75Delta ICD cell clone. The detection, performed by Cy3-conjugated anti-rabbit IgG or anti-mouse IgG, shows the localization of the respective p75NTR proteins in the plasmamembrane. Nuclei were blue-stained with 4',6-diamidino-2-phenylindole. C, expression of p75NTR mRNA (Northern blot) and D, protein levels (Western blot) of p75NTR in BENTR-free cell clone and in cell clones transfected with different constructs of p75NTR.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 2.   Epifluorescence microscopic analysis of cell damage by PrP-(106-126). A1 and A2, BEp75 cells control and treated for 72 h with 20 µM PrP-(106-126), respectively. B1 and B2, BENTR-free cells control and treated for 72 h with 20 µM PrP-(106-126), respectively. The intense yellow fluorescence by acridine orange in the nuclei (arrowheads) reveals the progressive chromatin condensation, collapse, and marginalization proper of apoptosis. The pale green fluorescence by acridine orange in the nuclei reveals the normal cells. The bright red fluorescence by ethidium bromide denotes nuclei of cells in which membrane integrity was lost as the death process had shifted from apoptosis to necrosis (arrows). +, mitosis.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 3.   Time-course and dose-response of the effect of PrP-(106-126). Time-course of the effect of PrP-(106-126) (20 µM) on BEp75 cells (A) and on BENTR-free cells (B). Data are reported as means ± S.D. of six experiments. C, dose-response effect of PrP-(106-126) on BEp75 and BENTR-free cells. Data are reported as means ± S.D. of three experiments.

Two mechanisms could be responsible for the function of p75NTR in the cell damage by the prion peptide. This receptor might be merely permissive for the cytotoxic action of PrP-(106-126) elicited via a mechanism independent of the actual binding of the peptide as in the case of excitotoxicity (22). Alternatively, the binding of prion peptide to p75NTR might be directly involved in cell death. A series of experimental findings shows that the latter mechanism is the most likely one.

First, we have treated SK-N-BE-derived cell clones expressing a truncated p75NTR (BEp75Delta ECD) (Fig. 1) lacking the four cysteine-rich repeats of the extracellular region either with PrP-(106-126) or with staurosporine. The results (Fig. 4) show that, while being still susceptible to staurosporine-elicited apoptosis, BEp75Delta ECD cells were insensitive to the cytotoxic effects of PrP-(106-126), a finding indicating the requirement of the extracellular region of p75NTR for the cytotoxic effect of PrP-(106-126).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 4.   Cell damage by PrP-(106-126) and by staurosporine in different cell clones. Data are reported as means ± S.D. of six experiments with BEp75 cells and of at least four experiments with the other clones. PrP-(106-126), 20 µM; staurosporine, 50 nM.

Second, we have shown that PrP-(106-126) binds to p75NTR. In fact, the results reported in Fig. 5A show that 125I-PrP-(106-126) binds to BEp75 cells but not to BENTR-free cells or to BEp75Delta ECD cells lacking the extracellular region of the receptor. The specificity of the binding was shown by its competitive inhibition by an excess of cold aggregated PrP-(106-126). Scatchard analysis (Fig. 5C) showed that the binding of the aggregated peptide to p75NTR occurs with a kd of 4.6 ± 0.7 nM (n = 4) and is saturable (Fig. 5B). The specificity of the binding was also shown by the finding that it was inhibited by the antibody sc-6189 raised against the amino terminus of p75NTR (Fig. 5D) and by NGF (Fig. 5E). Since NGF binds to p75NTR with a kd of 4-7 nM (18), which is similar to that of PrP-(106-126), the high concentration of NGF required for inhibiting the binding of the prion peptide may indicate that the two ligands interact with different sites of p75NTR.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 5.   Specific binding of 125I-PrP-(106-126) to p75NTR-expressing clones. A, binding of labeled peptide to whole cells of different clones in the presence or absence of unlabeled aggregated peptide. Data are reported as means ± S.D. of 18 experiments with BENTR-free and BEp75 clones and of six experiments with BEp75Delta ECD and BEp75Delta ICD clones. B, saturation curve of the peptide binding to cell clone expressing full-length p75NTR (BEp75), and C, the same data expressed as Scatchard plot. Data are of one experiment representative of four. D and E, concentration-dependent inhibition of the binding of peptide to cells expressing full-length p75NTR (BEp75) by antibody sc-6189 and by NGF, respectively. Data are of one experiment representative of three.

The results so far presented, showing that PrP-(106-126) is cytotoxic by binding to p75NTR, raise the problem of the role of this receptor in cell death induced by the peptide. Two mechanisms could be hypothesized. The binding of the prion peptide to p75NTR might be able to activate the receptor and trigger the signals for cell death via the receptor's intracellular region or it could serve solely as an anchorage allowing for PrP-(106-126)-induced cell damage via other mechanisms. We demonstrated the validity of the first hypothesis by investigating the effect of PrP-(106-126) on cell clones expressing a truncated p75NTR devoid of the entire intracellular region (BEp75Delta ICD) (Fig. 1). The results reported in Fig. 4 show that these cells, despite normally binding the peptide (Fig. 5A), were insensitive to its toxic effect indicating that the intracellular region of the receptor is necessary for signaling cell death.

We have also investigated some of the biochemical events usually involved in active cell death. The results (Fig. 6) demonstrate that p75NTR-mediated cell death induced by PrP-(106-126) is associated with the activation of caspases as it was fully suppressed by either Z-VAD-FMK (100 µM), a nonspecific inhibitor of caspases, or Z-IETD-FMK (20 µM), an inhibitor of receptor-activable caspase-8. These findings are consistent with the concept that prion peptide-elicited neuronal cell death via p75NTR is an active process that, by involving caspase-8, is reminiscent of the cell death induced by other members of the death receptors family (13). The data of Fig. 6 show that the cytotoxic effect of 50 nM staurosporine, a receptor-independent apoptogenic drug, was sensitive to Z-VAD-FMK but could not be suppressed by Z-IETD-FMK. The results of Fig. 6 also show that diphenyleneiodonium (100 nM), an inhibitor of NADPH oxidase, the enzyme forming reactive oxygen intermediates, and other flavo-protein dehydrogenases (23), could fully suppress the cell death by PrP-(106-126) mediated by p75NTR. This finding agrees with the notion that an oxidative stress is involved in the pathogenesis of cell damage by prion peptide (12).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of inhibitors on the cell damage by PrP-(106-126) and by staurosporine. Effect of the unspecific inhibitor of caspases (Z-VAD-FMK, 100 µM), of the specific inhibitor of caspase-8 (Z-IETD-FMK, 20 µM), and of an inhibitor of reactive oxygen intermediates-forming NADPH oxidase and other flavoprotein dehydrogenases (diphenyleneiodonium, 100 nM) on the neurotoxic action of PrP-(106-126) (20 µM) or staurosporine (50 nM) in BEp75 cells. Data are reported as means ± S.D. of at least four experiments.

Our results, showing that PrP-(106-126) damages neuronal cells by activating p75NTR, raise a series of problems to be investigated. These problems include the types of interaction such as the type of interaction of the prion peptide with the extracellular region of p75NTR, the signaling function of the different domains of the intracellular region, the identification of the events occurring down-stream the intracellular region (24, 25), and the comparison of the role of p75NTR with that of other cell surface proteins recently found to interact with prion peptide as the receptor for advanced glycation end-products (RAGE) (26), a 66-kDa protein with unknown function (27, 28), a 37-kDa laminin receptor precursor (29), the formyl peptide receptor-like 1 (30), and the PrPC itself (9).

The therapeutic and/or preventive strategies concerning the prion diseases are related to the mechanisms of formation and propagation of PrPSc and to the pathogenesis of the neuronal damage by PrPSc. It is likely that the results presented herein obtained by using the model of PrP-(106-126)-neurotoxic effect open new avenues for effective therapeutic strategies. Further studies will clarify if the neurotoxicity of purified infective PrPSc protein involves mechanisms similar to those of the PrP-(106-126) peptide.

    ACKNOWLEDGEMENTS

We thank Prof. S. Salvadori for the synthesis of PrP-(106-126) and Dr. M. Salmona (Istituto di Ricerche Farmacologiche Mario Negri (Milano, Italy) for the synthesis of scrambled PrP-(106-126).

    FOOTNOTES

* This work was supported by grants from Progetto Sanità 1996-97, Fondazione Cariverona (to F. R. and U. A.), Cofinanziamento Ministero dell'Università e della Ricerca Scientifica e Tecnologica-Università (to F. R. and U. A.), and from 5th Framework Program of the European Union Grant NOQLRT-1999-00573 (to G. D. V.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed. Tel.: 39-045-8027121; Fax: 39-045-8027127; E-mail: Filippo.Rossi@univr.it.

Published, JBC Papers in Press, August 6, 2001, DOI 10.1074/jbc.M107454200

    ABBREVIATIONS

The abbreviations used are: PrP, prion protein fragment; NGF, nerve growth factor; Z-VAD-FMK, benzyloxycarbonyl-Val-Ala-DL- Asp-fluoromethylketone; Z-IETD-FMK, benzyloxycarbonyl-Ile-Glu-Thr-Asp-fluoromethylketone; DPI, diphenyleneiodonium.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Prusiner, S. B. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 13636-13383
2. Aguzzi, A., and Weissmann, C. (1997) Nature 389, 795-798[CrossRef][Medline] [Order article via Infotrieve]
3. Forloni, G., Angeretti, N., Chiesa, R., Monzani, E., Salmona, M., Bugiani, O., and Tagliavini, F. (1993) Nature 362, 543-546[CrossRef][Medline] [Order article via Infotrieve]
4. Selvaggini, C., De Gioia, L., Cantù, L., Ghibaudi, E., Diomede, L., Passerini, F., Forloni, G., Bugiani, O., Tagliavini, F., and Salmona, M. (1993) Biochem. Biophys. Res. Commun. 194, 1380-1386[CrossRef][Medline] [Order article via Infotrieve]
5. Brown, D. R., Schmidt, B., and Kretzschmar, H. A. (1996) Nature 380, 345-347[CrossRef][Medline] [Order article via Infotrieve]
6. Florio, T., Thellung, S., Amico, C., Robello, M., Salmona, M., Bugiani, O., Tagliavini, F., Forloni, G., and Schettini, G. (1998) J. Neurosci. Res. 54, 341-352[CrossRef][Medline] [Order article via Infotrieve]
7. Rymer, D. L., and Good, T. A. (2000) J. Neurochem. 75, 2536-2545[CrossRef][Medline] [Order article via Infotrieve]
8. Ettaiche, M., Pichot, R., Vincent, J. P., and Chabry, J. (2000) J. Biol. Chem. 275, 36487-36490[Abstract/Free Full Text]
9. Brown, D. R. (2000) Biochem. J. 352, 511-518
10. Lin, M. C., Mirzabekov, T., and Kagan, B. L. (1997) J. Biol. Chem. 272, 44-47[Abstract/Free Full Text]
11. Kristensson, K., Feuerstein, B., Taraboulos, A., Hyun, W. C., Prusiner, S. B., and DeArmond, S. J. (1993) Neurology 43, 2335-2341[Abstract/Free Full Text]
12. Guentchev, M., Voigtlander, T., Haberler, C., Groschup, M. H., and Budka, H. (2000) Neurobiol. Dis. 7, 270-273[CrossRef][Medline] [Order article via Infotrieve]
13. Nagata, S. (1997) Cell 88, 355-365[CrossRef][Medline] [Order article via Infotrieve]
14. Frade, J. M., Rodriguez-Tebar, A., and Barde, A-Y. (1996) Nature 383, 166-168[CrossRef][Medline] [Order article via Infotrieve]
15. Bredesen, D. E., and Rabizadeh, S. (1997) Trends Neurosci. 20, 287-290[CrossRef][Medline] [Order article via Infotrieve]
16. Coulson, E. J., Reid, K., and Bartlett, P. F. (1999) Mol. Neurobiol. 20, 29-44[Medline] [Order article via Infotrieve]
17. Rabizadeh, S., Bittler, C. M., Butcher, L. L., and Bredesen, D. E. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10703-10706[Abstract/Free Full Text]
18. Yaar, M., Zhai, S., Pilch, P. F., Doyle, S. M., Eisenhauer, P. B., Fine, R. E., and Gilchrest, B. A. (1997) J. Clin. Invest. 100, 2333-2340[Medline] [Order article via Infotrieve]
19. Kuner, P., Schubenel, R., and Hertel, C. (1998) J. Neurosci. Res. 54, 798-804[CrossRef][Medline] [Order article via Infotrieve]
20. Bunone, G., Mariotti, A., Compagni, A., Morandi, E., and Della Valle, G. (1997) Oncogene 14, 1463-1470[CrossRef][Medline] [Order article via Infotrieve]
21. Spector, D. L., Goldman, R. D., and Leinwald, L. A. (1998) Cells, A Laboratory Manual , Vol. 1 , pp. 15.6-15.7, Cold Spring Harbor Laboratory Press
22. Oh, J. D., Chartisathian, K., Chase, T. N., and Butcher, L. L. (2000) Brain Res. 853, 174-185[CrossRef][Medline] [Order article via Infotrieve]
23. O'Donnell, B. V., Tew, D. G., Jones, O. T., and England, P. J. (1993) Biochem. J. 290, 41-49
24. Kaplan, D. R., and Miller, F. D. (2000) Curr. Opin. Neurobiol. 10, 381-391[CrossRef][Medline] [Order article via Infotrieve]
25. Meldolesi, J., Sciorati, C., and Clementi, E. (2000) Trends Pharmacol. Sci. 21, 242-243[CrossRef][Medline] [Order article via Infotrieve]
26. Yan, S. D., Zhu, H., Zhu, A., Golabek, A., Du, H., Roher, A., Yu, J., Soto, C., Schmidt, A. M., Stern, D., and Kindy, M. (2000) Nat. Med. 6, 643-651[CrossRef][Medline] [Order article via Infotrieve]
27. Martins, V. R., Graner, E., Garcia-Abreu, J., Souza, S. J., Mercadante, A. F., Veiga, S. S., Zanata, S. M., Neto, V. M., and Brentani, R. R. (1997) Nat. Med. 3, 1376-1382[CrossRef][Medline] [Order article via Infotrieve]
28. Martins, V. R., Mercadante, A. F., Cabral, A. L. B., Freitas, A. R. O., and Castro, R. M. R. P. S. (2001) Braz. J. Med. Biol. Res. 34, 585-595[Medline] [Order article via Infotrieve]
29. Rieger, R., Edenhofer, F., Lasmézas, C. I., and Weiss, S. (1997) Nat. Med. 3, 1383-1388[CrossRef][Medline] [Order article via Infotrieve]
30. Le, Y., Yazawa, H., Gong, W., Yu, Z., Ferrans, V. J., Murphy, P. M., and Wang, J. M. (2001) J. Immunol. 166, 1448-1451[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Virol.Home page
C. Tuffereau, K. Schmidt, C. Langevin, F. Lafay, G. Dechant, and M. Koltzenburg
The Rabies Virus Glycoprotein Receptor p75NTR Is Not Essential for Rabies Virus Infection
J. Virol., December 15, 2007; 81(24): 13622 - 13630.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
A. R. Taylor, D. J. Gifondorwa, J. M. Newbern, M. B. Robinson, J. L. Strupe, D. Prevette, R. W. Oppenheim, and C. E. Milligan
Astrocyte and Muscle-Derived Secreted Factors Differentially Regulate Motoneuron Survival
J. Neurosci., January 17, 2007; 27(3): 634 - 644.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Pietri, A. Caprini, S. Mouillet-Richard, E. Pradines, M. Ermonval, J. Grassi, O. Kellermann, and B. Schneider
Overstimulation of PrPC Signaling Pathways by Prion Peptide 106-126 Causes Oxidative Injury of Bioaminergic Neuronal Cells
J. Biol. Chem., September 22, 2006; 281(38): 28470 - 28479.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
M. L. Florez-McClure, D. A. Linseman, C. T. Chu, P. A. Barker, R. J. Bouchard, S. S. Le, T. A. Laessig, and K. A. Heidenreich
The p75 Neurotrophin Receptor Can Induce Autophagy and Death of Cerebellar Purkinje Neurons
J. Neurosci., May 12, 2004; 24(19): 4498 - 4509.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Bate, M. Salmona, L. Diomede, and A. Williams
Squalestatin Cures Prion-infected Neurons and Protects Against Prion Neurotoxicity
J. Biol. Chem., April 9, 2004; 279(15): 14983 - 14990.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
M. V. Chao
Dependence Receptors: What Is the Mechanism?
Sci. Signal., September 16, 2003; 2003(200): pe38 - pe38.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
F. C. Bronfman, M. Tcherpakov, T. M. Jovin, and M. Fainzilber
Ligand-Induced Internalization of the p75 Neurotrophin Receptor: A Slow Route to the Signaling Endosome
J. Neurosci., April 15, 2003; 23(8): 3209 - 3220.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
D. B. Jacoby
Airway Neural Plasticity: The Nerves They Are A-Changin'
Am. J. Respir. Cell Mol. Biol., February 1, 2003; 28(2): 138 - 141.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Langevin, H. Jaaro, S. Bressanelli, M. Fainzilber, and C. Tuffereau
Rabies Virus Glycoprotein (RVG) Is a Trimeric Ligand for the N-terminal Cysteine-rich Domain of the Mammalian p75 Neurotrophin Receptor
J. Biol. Chem., September 27, 2002; 277(40): 37655 - 37662.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. B. Brann, M. Tcherpakov, I. M. Williams, A. H. Futerman, and M. Fainzilber
Nerve Growth Factor-induced p75-mediated Death of Cultured Hippocampal Neurons Is Age-dependent and Transduced through Ceramide Generated by Neutral Sphingomyelinase
J. Biol. Chem., March 15, 2002; 277(12): 9812 - 9818.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/42/38929    most recent
M107454200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Della-Bianca, V.
Right arrow Articles by Della Valle, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Della-Bianca, V.
Right arrow Articles by Della Valle, G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.